Ahn-Gook Pharmaceutical Co. Ltd (001540) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ahn-Gook Pharmaceutical Co. Ltd (001540) has a cash flow conversion efficiency ratio of 0.086x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩14.44 Billion ≈ $9.79 Million USD) by net assets (₩167.29 Billion ≈ $113.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ahn-Gook Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Ahn-Gook Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Ahn-Gook Pharmaceutical Co. Ltd carry for a breakdown of total debt and financial obligations.
Ahn-Gook Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ahn-Gook Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chegg Inc
NYSE:CHGG
|
-0.075x |
|
Unick Corporation
KQ:011320
|
0.054x |
|
AmeriServ Financial Inc
NASDAQ:ASRV
|
-0.028x |
|
Everbrite Technology Co Ltd
TWO:4523
|
-0.042x |
|
Scherzer & Co. AG
F:PZS
|
N/A |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
-0.063x |
|
Norcod As
OL:NCOD
|
-0.333x |
|
Cobre Ltd
AU:CBE
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Ahn-Gook Pharmaceutical Co. Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Ahn-Gook Pharmaceutical Co. Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Ahn-Gook Pharmaceutical Co. Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩165.68 Billion ≈ $112.28 Million |
₩4.91 Billion ≈ $3.33 Million |
0.030x | +438.78% |
| 2023-12-31 | ₩151.67 Billion ≈ $102.78 Million |
₩-1.33 Billion ≈ $-899.86K |
-0.009x | -175.78% |
| 2022-12-31 | ₩154.80 Billion ≈ $104.90 Million |
₩1.79 Billion ≈ $1.21 Million |
0.012x | +14.00% |
| 2021-12-31 | ₩145.26 Billion ≈ $98.44 Million |
₩1.47 Billion ≈ $997.66K |
0.010x | -86.95% |
| 2020-12-31 | ₩144.10 Billion ≈ $97.65 Million |
₩11.19 Billion ≈ $7.58 Million |
0.078x | -47.86% |
| 2019-12-31 | ₩148.25 Billion ≈ $100.46 Million |
₩22.08 Billion ≈ $14.96 Million |
0.149x | +1919.68% |
| 2018-12-31 | ₩146.77 Billion ≈ $99.46 Million |
₩-1.20 Billion ≈ $-814.03K |
-0.008x | -106.42% |
| 2017-12-31 | ₩136.96 Billion ≈ $92.81 Million |
₩17.46 Billion ≈ $11.84 Million |
0.128x | +32.23% |
| 2016-12-31 | ₩130.89 Billion ≈ $88.70 Million |
₩12.62 Billion ≈ $8.55 Million |
0.096x | -33.85% |
| 2015-12-31 | ₩131.06 Billion ≈ $88.82 Million |
₩19.11 Billion ≈ $12.95 Million |
0.146x | +1287.76% |
| 2014-12-31 | ₩122.46 Billion ≈ $82.99 Million |
₩1.29 Billion ≈ $871.80K |
0.011x | -63.54% |
| 2013-12-31 | ₩126.42 Billion ≈ $85.67 Million |
₩3.64 Billion ≈ $2.47 Million |
0.029x | -71.39% |
| 2012-12-31 | ₩114.36 Billion ≈ $77.50 Million |
₩11.51 Billion ≈ $7.80 Million |
0.101x | -- |
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.